The US Food and Drug Administration (FDA) has granted approval for Foundation Medicine’s FoundationOne Liquid CDx as a companion diagnostic for Pfizer’s Braftovi (encorafenib) in combination with cetuximab.

The combination therapy received approval from the FDA for previously treated metastatic colorectal cancer (mCRC) patients with a BRAF V600E alteration.

With the approval, FoundationOne Liquid CDx becomes the first comprehensive genomic profiling test to be approved by the FDA to detect patients with BRAF V600E mutations in mCRC who may benefit from treatment with the combination therapy.

Foundation Medicine chief medical officer Dr Mia Levy said: “Companion diagnostics are high-quality, well-validated genomic tests that provide critical information to help oncologists make informed treatment decisions for their patients.

“This new companion diagnostic indication for FoundationOne Liquid CDx provides oncologists with an important, non-invasive genomic testing option for metastatic patients with this difficult-to-treat condition.”

The prescription-only FoundationOne Liquid CDx is a qualitative in vitro diagnostic test that leverages next-generation sequencing technology to identify cancer patients with advanced solid tumours.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This test holds the capability to assess more than 300 cancer-related genes from a simple blood sample, offering better genomic insights.

It uses circulating cell-free DNA to specifically analyse 324 genes.

Furthermore, the test obtained FDA approval to report short variants in 311 genes and to serve as a companion diagnostic to detect patients who may be qualified for treatment with specific therapies.

Last week, Foundation Medicine launched a new tissue-naive circulating tumour DNA (ctDNA) monitoring assay named FoundationOn Monitor.

This assay is intended for use in retrospective studies and offers research insights into treatment response and resistance using a blood sample.